INTRODUCTION
Rearrangements of the short arm of human chromosome 1 occur frequently in a variety of human cancers, with 1p36 deletion being a prevalent lesion (Bagchi and Mills, 2008) . We previously identified Chromodomain Helicase DNA binding protein 5 (CHD5) as a tumor suppressor mapping to 1p36, and discovered that it is frequently deleted in human glioma (Bagchi et al., 2007) . Recent studies have indicated that in addition to being commonly deleted, CHD5 is epigenetically silenced (Koyama et al., 2012; Mokarram et al., 2009; Mulero-Navarro and Esteller, 2008; Wang et al., 2009b; Zhao et al., 2011) or mutated (Agrawal et al., 2011; Berger et al., 2011; Gorringe et al., 2008; Jones et al., 2010; Lang et al., 2011; Li et al., 2011; Okawa et al., 2008; Robbins et al., 2011; Sjö blom et al., 2006; Cancer Genome Atlas Research Network, 2008 in a variety of human cancers. CHD5 expression is also a favorable predictor of survival following anticancer therapy (Du et al., 2012; Garcia et al., 2010; Koyama et al., 2012; Wong et al., 2011) .
CHD5 is a member of the CHD protein family, a group of nine proteins (CHD1-CHD9) that are defined by dual chromodomains as well as SWI/SNF-like ATP-dependent helicase motifs (Marfella and Imbalzano, 2007; Sims and Wade, 2011) . For CHD1, these motifs have been implicated in nucleosome mobilization (Lusser et al., 2005) . CHD proteins have been shown to mediate transcriptional activation, repression, and elongation (Murawska and Brehm, 2011) . Although some chromodomains bind methylated histones (Flanagan et al., 2005; Jacobs and Khorasanizadeh, 2002; Nielsen et al., 2002) , the chromodomains of CHD4 do not bind histone tails, but instead bind DNA directly (Bouazoune et al., 2002) . CHD5, like its closest members CHD3 and CHD4, has tandem plant homeodomains (PHDs; Figure 1A ). Growing evidence implicates PHDs as readers of specifically modified or unmodified histones (Godfried et al., 2002; Koh et al., 2008; Lan et al., 2007; Mansfield et al., 2011; Matthews et al., 2007; Musselman et al., 2009 Musselman et al., , 2012 Ooi et al., 2007; Org et al., 2008; Rajakumara et al., 2011; Saksouk et al., 2009; Shi et al., 2006 Shi et al., , 2007 Tsai et al., 2010; Wang et al., 2009a; Wysocka et al., 2006) . The PHD-mediated histone interaction appears to be functionally important because its perturbation is associated with various human diseases, including immunological disorders, neurological syndromes, and cancer (Baker et al., 2008) . Given CHD5's pivotal role in human cancer, we sought to elucidate its mechanism of tumor suppression by determining the ability of its PHDs to bind specific histone marks. Here we demonstrate that the dual PHDs of Chd5 mediate binding specifically to the N terminus of H3 lacking posttranslational modifications, and define this interaction as being essential for Chd5 to inhibit cellular proliferation, modulate gene expression, induce differentiation, and effectively suppress tumorigenesis in vivo.
RESULTS

Chd5-PHDs Bind the N Terminus of Unmodified H3
We screened histone peptide arrays with tagged purified polypeptides encompassing the tandem PHDs of Chd5 and identified specific binding with N-terminally unmodified H3 peptides (unmodified residues 2, 3, and 4 of H3; Figures 1B and S1A) . We confirmed the specificity of PHD interactions with unmodified H3, H3K4me1, H3K4me2, and H3K4me3 using in vitro peptide pull-down assays ( Figure 1C ). Similar assays using individual PHDs indicated that although PHD1 and PHD2 had the same binding preference for H3K4me0, PHD2 had the highest (H) Only 38% (represented by the gray box) of Chd5 and H3K4me3 overlapping peaks are within 100 bp of each other. Negative or positive distance indicates that the H3K4me3 peak is upstream or downstream, respectively, of the Chd5 peak relative to the transcriptional orientation of the gene. The distribution is skewed toward Chd5-bound peaks being upstream of the H3K4me3-bound peaks (positive distance), i.e., away from the gene body. See also Figure S1 , Table S1, and Table S2. affinity ( Figures S1B and S1C ). Endogenous Chd5 also bound preferentially to H3K4me0 and did not bind to H3K4me3, a mark that is characteristic of transcriptionally active genes ( Figures 1D and S1D ). In agreement with a previous report that PHDs of both CHD5 and its close family member CHD4 bind N-terminally unmodified H3 , our findings indicate that the PHDs of Chd5 bind to unmodified H3, and that this interaction is disrupted by posttranslational modifications of extreme N-terminal residues of H3. reciprocal to that of H3K4me3. Using immunofluorescence in primary mouse embryonic fibroblasts (MEFs), we found Chd5 expressed in two different patterns: in small dots throughout the nucleus, or in a punctate pattern overlapping with DAPI-enriched regions ( Figure 1E ). Expression analyses indicated that whereas Chd5 and H3K4me3 did not significantly overlap, the punctate pattern of Chd5 overlapped with H3K9me3, a mark of heterochromatin ( Figures S1E-S1G ).
To determine whether this inverse correlation between Chd5 and H3K4me3 was evident at the genomic level, we used chromatin immunoprecipitation followed by DNA sequencing (ChIPseq) to identify Chd5-bound and H3K4me3-bound loci, and compared their correlations across the genome. Annotation of peaks to Refseq genes indicated that the majority (61.7%) of Chd5-bound peaks were within 2 kilobase (kb) of the transcription start site (TSS) of known genes ( Figures 1F and S1H ). Because H3K4me3 preferentially marks TSS (Barski et al., 2007) , we restricted our analysis to high-confidence peaks within this interval (Table S1 ; accession number SRA062358). The majority (63.5%) of these gene-proximal Chd5-peaks mapped to genes lacking H3K4me3-peaks ( Figure S1I ). Out of the large fraction of genes whose TSS overlaps with H3K4me3 peaks, there was a depletion of Chd5 peaks that was 1.2-fold less than what would be expected randomly. Because of the small number of Chd5-bound regions, this depletion was just over the threshold for statistical significance (p < 0.08, corrected Fisher; Table S2 ). When the nucleotide sequence of the peaks was considered, only 32.8% of the nucleotides overlapped between H3K4me3-enriched region reads and Chd5-peaks (Figure 1G) . Out of the small percentage of peaks mapping to the same vicinity (36.5%; see Figure S1I ), the majority (62%) were spaced >100 nucleotides from each other, and most of the peaks were oriented such that the Chd5-peak was upstream of the H3K4me3-peak ( Figures 1H and S1I ). The read counts and ChIP quantitative PCR (qPCR) analysis in the vicinity of several representative Chd5-bound genes indicate that most Chd5-bound loci lack H3K4me3 (Figures S1J and S1K). These data indicate that the majority of Chd5-bound loci lack H3K4me3 in vivo, in agreement with our in vitro findings.
Mutation of Specific Conserved PHD Residues
Abrogates the Chd5-H3 Interaction To identify Chd5-PHD residues that are important for the interaction with unmodified H3, we compared the PHDs of Chd5 with the PHDs of the closest family members, Chd3 and Chd4 (Figure 2A) . We used site-specific mutagenesis to generate a series of full-length Chd5 constructs with mutations in individual conserved PHD residues, including some amino acids corresponding to those that were previously characterized for human CHD4 (Mansfield et al., 2011; Musselman et al., 2009 Musselman et al., , 2012 Figure 2B) . Chromatin fractions from cells expressing Flag-tagged Chd5 indicated that wild-type (WT) Chd5, as well as versions of Chd5 with single amino acid mutations, is associated with chromatin ( Figure S2A ). However, in vitro assays with unmodified H3 peptides and with either purified Chd5-PHDs ( Figures  2C, 2D , S2B, and S2C) or nuclear lysates expressing Flagtagged Chd5 (WT or those with single amino acid mutations; Figures 2E and S2D ) indicated that several Chd5 residues are critical for facilitating the H3 interaction. These analyses suggest that PHD1-D346A, PHD2-E414A, and PHD2-E419A bind H3 more efficiently than PHD1-D361A, PHD2-D434A, and PHD2-D415A.
The Chd5-H3 Interaction is Critical for Chd5's Ability to Inhibit Cellular Proliferation To determine whether PHD-mediated binding to H3 is functionally important for Chd5 activity, we compared full-length WT Chd5 with Chd5-PHD mutants in terms of their ability to inhibit cellular proliferation. WT Chd5 proved to be such a potent inhibitor of proliferation that it was necessary to express it in a regulated fashion; therefore, we developed a tetracycline-inducible system (Zuber et al., 2011) by expressing WT and mutant Chd5 in primary Rosa reverse tetracycline transactivator (rtTA)-expressing MEFs ( Figures S3A-S3C ). Whereas doxycycline (dox) treatment of vector-expressing MEFs had no significant effect ( Figure S3D ), dox-induced expression of WT Chd5 inhibited proliferation ( Figure 3A ), consistent with our previous findings that proliferation is compromised in MEFs derived from mice engineered to have an extra copy of the genomic region encompassing Chd5 (Bagchi et al., 2007) .
To functionally define residues that are critical for inhibiting proliferation, we assayed a series of Chd5-PHD mutants for their effect on proliferation using the dox-inducible system. Whereas inducible expression of the H3-binding-competent Chd5-PHD mutants D346A or W384A inhibited proliferation to an extent comparable to that observed for WT Chd5, Chd5 mutants that are compromised for H3 binding (G355A, D361A, D415A, C432W, and D434A) were defective in their ability to inhibit proliferation ( Figures 3A and S3D ). Whereas D346A inhibited proliferation, this was not the case in the context of a second mutation at D434, indicating that perturbation of a single PHD-H3 interaction in one PHD overrides the ability of the other PHD to compensate. These findings indicate that PHD-mediated binding to unmodified H3 is essential for Chd5 to inhibit proliferation.
Chd5 Transcriptionally Modulates Genes Implicated in Cancer, whereas H3-Binding-Incompetent Chd5-PHD Mutants Fail to Do So Genome-wide ChIP-seq analysis indicated that the majority of Chd5-bound peaks were located in promoters, 5 0 untranslated regions (UTRs), and early introns (see Figures 1F and S1H ), supporting the idea that Chd5 plays a role in transcriptional modulation. Pathway analysis of the candidate Chd5-modulated genes identified by ChIP-seq showed enrichment for proteins implicated in cancer ( Figure 3B ; Tables S3 and S4 ). To validate specific candidate genes as being Chd5 modulated, we analyzed their expression in primary MEFs in which Chd5 was overexpressed or knocked down ( Figures 3C and S3E ). Indeed, expression of several Chd5 targets correlated with Chd5 expression. Whereas mutants D346A and W384A were able to inhibit both the proliferation and expression of several Chd5-bound genes, mutant versions of Chd5 that were defective in their ability to inhibit proliferation (G355A, D361A, D434A, and C432W) were not able to inhibit expression of Chd5-bound loci. These findings indicate that PHD-mediated H3 binding is critical for the ability of Chd5 to transcriptionally modulate its targets, including genes that have been implicated in Wnt signaling, chromatin remodeling, and cell-cycle regulation, highlighting Chd5's role in pathways that were previously implicated in tumor suppression (Hers et al., 2011; Musgrove et al., 2011; Yadav et al., 2009; Yao et al., 2011) .
The Inability of Chd5-PHD Mutants to Bind H3 Causes Oncogenic Transformation and Robust Tumorigenesis In Vivo The above findings indicate that PHD-mediated H3 binding is essential for Chd5 to inhibit proliferation and to transregulate genes encoding components of cancer-associated pathways. We next investigated the extent to which perturbation of the PHD-mediated Chd5-H3 interaction leads to cancer. We previously reported that Chd5-compromised MEFs were sensitized to oncogenic transformation and thus predisposed to tumori- (E) H3 peptide pull-down assays with nuclear extracts prepared from MEFs expressing Flagtagged WT Chd5 or the Chd5-PHD mutants, followed by immunoblotting with an anti-Flag antibody, indicate that whereas the WT Chd5 and the Chd5-D346A mutant are pulled down by H3 peptide, the Chd5-D361A and D434A mutant proteins are not. See also Figure S2 . genesis in vivo (Bagchi et al., 2007) . Therefore, we assessed whether cells expressing functionally compromised Chd5-PHD mutants were prone to Rasinduced transformation and tumorigenesis in vivo. rtTA MEFs coexpressing RasG12D and dox-inducible constructs encoding WT or mutant versions of Chd5 were injected subcutaneously into two cohorts of athymic nude mice. One cohort of mice received regular food, whereas the other cohort received a dox-containing diet to induce expression of WT Chd5 or the Chd5-PHD mutants, and tumorigenesis was monitored (Table S5 ). Whereas expression of WT Chd5 did not lead to tumor formation, cells expressing mutant Chd5 formed tumors with a severity that correlated inversely with their ability to bind H3, i.e., D361A and D434A caused robust tumor development, and fewer and significantly smaller tumors formed in response to D346A (Figures 3D and  S3F ). Furthermore, tumors that arose from MEFs expressing Chd5-PHD mutants that cannot bind H3 (D361A and D434A) expressed Chd5 target genes at higher levels relative to the smaller tumors that developed from MEFs expressing WT Chd5 or D346A ( Figure 3E ). These findings demonstrate that perturbation of the Chd5-H3 interaction dramatically enhances tumorigenesis in vivo. The Chd5-H3 Interaction Is Essential for Inhibition of Proliferation, Induction of Differentiation, and Suppression of Tumor Growth of Human Neuroblastoma Cells Given that CHD5 inactivation has been implicated in a variety of human cancers, including neuroblastomas Garcia et al., 2010 Garcia et al., , 2012 , we asked whether induction of WT or mutant Chd5 in a CHD5-deficient context could enforce tumor suppression in human cancer cells. We chose the human neuroblastoma cell line SK-N-AS, which has a 1p36.33-1p36.2 deletion (Kaghad et al., 1997) encompassing the CHD5 locus. Endogenous CHD5 is absent or expressed at very low levels in this cell line ( Figure S4A ; Garcia et al., 2010) . To establish SK-N-AS cells in which we could express Chd5 in a regulated fashion, we generated SK-N-AS cells that stably express rtTA, and introduced dox-inducible WT or mutant versions of Chd5 using retroviral infection ( Figures S4B and S4C) . Although induction of both WT Chd5 and D346A inhibited proliferation (Figure 4A) , we observed only an $17% reduction, compared with the striking 54% inhibition of proliferation in MEFs (see Figure 3A) . This finding is consistent with the fact that p53, a downstream effector of Chd5-mediated tumor suppression (Bagchi et al., 2007) , is inactivated in SK-N-AS cells (Goldschneider et al., 2006) . Interestingly, human neuroblastoma cells expressing WT Chd5 had differentiated features, such as a flat epitheliallike morphology and increased expression of the neuronal marker MAP2, which contrasted markedly with the phenotype of cells expressing either control vector or the H3 bindingimpaired PHD mutants (Chd5-D361A or Chd5-D434A), which had the classic stem-like neuroblastoma morphology with proliferative foci and lower expression of MAP2 ( Figures 4B and S4D) . Cells expressing the Chd5-D346A mutant had a partially differentiated morphology. This analysis indicated that PHD-mediated H3 binding is essential for Chd5 to inhibit proliferation and to induce differentiation of human neuroblastoma cells.
To assess the tumorigenic potential of Chd5-expressing human neuroblastoma cells, we injected cells subcutaneously into two different cohorts of athymic nude mice: one receiving normal food and one receiving dox-containing food (Table S6 ; Figure S4E ). Whereas expression of WT Chd5 resulted in an $30% reduction in overall tumor volume, expression of the H3-binding-compromised Chd5-PHD mutants (Chd5-D361A or Chd5-D434A) failed to reduce tumor growth, and instead enhanced overall tumor volume by 30%-50% ( Figures 4C and   4D ). This demonstrates that induction of WT Chd5 suppresses tumorigenesis in vivo.
DISCUSSION
Since the time that CHD5 was first reported as a tumor suppressor mapping to human 1p36 (Bagchi et al., 2007) , its inactivation has been documented in a diverse array of human cancers (Agrawal et al., 2011; Berger et al., 2011; Gorringe et al., 2008; Jones et al., 2010; Koyama et al., 2012; Lang et al., 2011; Li et al., 2011; Mokarram et al., 2009; Mulero-Navarro and Esteller, 2008; Okawa et al., 2008; Robbins et al., 2011; Cancer Genome Atlas Research Network, 2011; Wang et al., 2009b; Zhao et al., 2011) , which indicates that CHD5 regulates processes that are fundamental for cancer prevention. Therefore, defining how CHD5 protects against tumorigenesis may affect the treatment of a variety of human cancers. Although it belongs to a protein family that includes members implicated in chromatin remodeling, the mechanism by which CHD5 exerts its tumor-suppressive role has been largely unexplored. Here, we demonstrate that the ability of Chd5 to bind unmodified H3 is essential for tumor suppression.
By focusing on the mechanism by which CHD5 interacts with chromatin, we discovered that the tandem PHDs mediate binding to N-terminally unmodified H3. PHDs are modules that were initially identified in plant homeodomain (PHD) proteins; subsequently, PHD-containing proteins were discovered in yeast, flies, and humans, especially in chromatin-associated and nuclear proteins. Although the zinc-binding motifs of PHD motifs are well conserved, diversity in the ligand-binding residues generates versatility in their interaction partners. PHDs are histone readers that control gene expression cascades by recruiting multiprotein complexes consisting of chromatin regulators and transcription factors. Many PHDs specifically bind the N terminus of H3, with different PHDs recognizing H3K4me2/3 versus H3K4me0, H3R2me0 versus H3R2me2, methylation at H3K9 or H3K36, or acetylation at H3K14 (Sanchez and Zhou, 2011) . Our findings are in agreement with a recent report demonstrating that PHDs of CHD5 are most homologous to H3K4me0-readers, including those of the BRAF35-HDAC complex protein BHC80 (Lan et al., 2007) , Autoimmune Regulator (AIRE; Koh et al., 2008; Org et al., 2008) , Tripartite Motif-containing protein 24 (TRIM24) (Tsai et al., 2010) , DNA (cytosine-5)-Methyltransferase 3-like protein (DNMT3L) (Ooi (C) Chd5 transcriptionally represses target gene expression, whereas H3-binding mutants fail to do so. qRT-PCR analyses of RNA derived from MEFs with either enhanced (WT+) or compromised (Chd5-KD) Chd5, vector control, or expressing Chd5-PHD mutants indicates that whereas both WT Chd5 and Chd5 PHD mutant D346A repress target gene expression, Chd5 PHD mutants that are unable to bind H3 (D361A, D434A, and D346A/D434A) fail to do so. Data were normalized with actin, presented as mean ± SD. Fold change was calculated by comparing MEFs with (+) and without (À) dox. Asterisk indicates Student's two-tailed t test (p value < 0.001). (D) Chd5 PHD mutants that cannot bind H3 form robust tumors in vivo. MEFs expressing RasG12D and either dox-inducible WT Chd5 or Chd5 PHD mutants were injected subcutaneously into athymic nude mice, and tumor formation was monitored. Y axis denotes tumor volume; X axis denotes the days after dox was provided in the diet. Kinetics of tumor growth of untreated (red circles) and treated (blue squares) mice are shown, with data represented as mean ± SD. (NB: Although some injection sites developed lesions, these lesions were extremely small [*] . The large tumor made it necessary to sacrifice this mouse at day 26 [**]). See Table S5 for detailed tumor data. (E) Tumors developing from cells expressing Chd5 PHD mutants (D361A and D434A) have derepression of Chd5 target genes. Tumor RNA was analyzed by qRT-PCR. Data were normalized with actin, and the fold change was derived by comparing tumors with the small lesion that developed in MEFs expressing WT Chd5. Data are presented as mean ± SEM. See also Figure S3 , Table S3, and Table S4 . (Mansfield et al., 2011; Musselman et al., 2009 Musselman et al., , 2012 . These PHDs lack the aromatic cage characteristic of PHDs that specifically bind H3K4me2/3.
We identified key residues of Chd5 PHDs that are conserved among the close family members Chd3 and Chd4, and are essential for mediating the H3 interaction. Mutation of these residues (D361 in Chd5-PHD1, as well as D415 or D434 in Chd5-PHD2) abrogates the Chd5-H3 interaction, compromising Chd5's cellular role in inhibiting proliferation, inducing differentiation, and suppressing tumorigenesis. Perturbation of H3K4me0 PHD readers has been associated with several human malignancies. For example, mutations in AIRE are associated with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (Koh et al., 2008; Org et al., 2008) , and TRIM24 expression correlates inversely with survival of breast cancer patients (Tsai et al., 2010) . Our findings herein define Chd5 as an H3-interacting protein and provide a functional link between the CHD class of H3K4me0 PHD readers and suppression of tumorigenesis.
Previous work indicated that CHD5 facilitates expression of a tumor-suppressive network that includes p16 and p19 encoded by the Cdkn2a locus (Bagchi and Mills, 2008; Bagchi et al., 2007) . Whereas Chd5 loss enhances proliferation by compromising expression of p16/Rb and p19/p53-mediated tumor-suppressive pathways, gain of the genomic interval encompassing Chd5 compromises proliferation by excessively activating these pathways. Excessive activation of p16/Rb and p19/p53-mediated tumor-suppressive pathways causes apoptosis, cellular senescence, and neonatal death, which are dependent on p16, p19, and p53. Here, we demonstrate for that inducible expression of WT Chd5 inhibits proliferation, but mutant versions of Chd5 that are not able to bind H3 fail to do so. We found that in addition to binding Cdkn2a, Chd5 binds and regulates the expression of multiple loci across the genome, the majority of which lack the active H3K4me3 mark that we found abrogates Chd5 binding in vitro. The finding that Chd5 peaks are often upstream of adjacent H3K4me3 peaks suggests that Chd5 binding facilitates the recruitment of additional protein complexes that deposit the H3K4me3 mark, which is characteristic of transcriptionally active genes. While our findings extend our previous studies that first linked Chd5 to Cdkn2a (Bagchi et al., 2007) , here we show that an extensive number of additional cancer-associated loci are bound and regulated by Chd5. These include genes encoding proteins that have been implicated in chromatin dynamics and cancer-associated pathways. Thus, in addition to regulating Cdkn2a, a pivotal locus in tumorigenesis, Chd5 modulates the expression of multiple genes that regulate pathways that impinge upon the tumorigenic process.
The finding that CHD5 status is a prognostic indicator of survival following anticancer therapy for gallbladder carcinoma, neuroblastoma, and ovarian cancer (Du et al., 2012; Garcia et al., 2010; Koyama et al., 2012; Wong et al., 2011) suggests that CHD5-modulated pathways are effective targets for anticancer therapies. The heterozygous nature of CHD5 mutations in human cancer raises the possibility that therapies that induce expression of WT CHD5 could enforce tumor suppression. To address this issue, it will be important to determine the extent to which the WT allele is silenced by DNA methylation in human cancers. Our finding that expression of mutant versions of Chd5 defective in H3 binding has a dominant negative effect on endogenous Chd5/CHD5, leading to enhanced tumorigenesis reminiscent of Chd5 loss, cautions that effective therapeutic strategies will need to specifically induce expression of WT but not mutant versions of CHD5. In addition, CHD5 levels must be carefully controlled to avoid deleterious effects, as even one extra copy of Chd5 causes excessive apoptosis and embryonic lethality (Bagchi et al., 2007) . Given our finding that tumor growth could be inhibited in human neuroblastoma cells even in the context of p53 deficiency, it is likely that CHD5's multifaceted ways to enforce tumor suppression will prove useful for regulating diverse types of cancers, including those that involve combinations of genetic lesions. The fact that CHD5 is a member of the Trithorax-group (TrxG) proteins, which oppose Polycombgroup (PcG)-mediated gene expression cascades (Mills, 2010) , suggests that strategies that inhibit PcG-mediated chromatin dynamics could enforce CHD5 activity effectively without the deleterious effects of inducing apoptosis or cellular senescence. Our finding that Chd5 inhibits expression of the oncogenic PcG protein Bmi1 indicates that Chd5 inhibits PcG-mediated chromatin dynamics at multiple levels.
In summary, this work defines a specific histone mark that is bound by Chd5 and is required for its ability to regulate transcriptional cascades, inhibit proliferation, induce differentiation, and efficiently suppress tumorigenesis in vivo. These findings implicate Chd5 as a member of the newly appreciated class of unmodified H3-binding proteins, and provide mechanistic insight into Chd5-mediated tumor suppression.
EXPERIMENTAL PROCEDURES Plasmid Construction and Retroviral Expression System
Mouse Chd5 cDNA from KK DNAFORM and Geneservice Ltd (Clone ID: M5C1079M20) was used as a template for generating PCR products to clone the PHDs and the full-length Chd5 cDNA. The PHDs were cloned into pGEX-6P1 (Clontech). The dox-inducible retroviral expression system was generated by cloning full-length Chd5 into pmCherry-C1 (Clontech) at the BglII/SalI restriction site, removing cherry-Chd5 by NheI/SalI cleavage, and ligating to a XbaI/XhoI-cut modified version of TtRMPV-PGK-HygroR (Zuber et al., 2011) or TtRMPV-PGK-PuroR plasmid (see Figure S3A) . The pMSCV-GFP-IRES-mNras G12D plasmid (Zuber et al., 2009 ) was provided by S. Lowe. Mutations were generated by site-directed mutagenesis, and all plasmids were confirmed by sequencing. The small hairpin RNA (shRNA) construct used for knocking down Chd5 (shChd5-WZ) was cloned into the MLP retroviral vector. Retroviral infection is described in the Extended Experimental Procedures. See also Figure S4 and Table S6 . 
Recombinant Protein Production and Purification
Chd5-PHD glutathione S-transferase (GST) fusion proteins were produced by inducing 1-2 L of bacterial cultures (in Luria Bertani [LB] medium containing 50 mM zinc chloride) with 0.1 mM IPTG (A 600 = 0.6), followed by a 14 hr incubation at 18 C. Bacterial pellets were lysed in 100 mM Tris pH 7.5, 400 mM NaCl, 5 mM dithiothreitol (DTT), 0.1 mg/ml lysozyme, and protease inhibitor tablets (Roche), and cleared lysates were treated with polyethyleneimine before purification. The GST-PHDs were purified by binding with glutathione-agarose (Sigma) and eluted with reduced glutathione (Sigma). The eluate was dialyzed in 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 1 mM DTT overnight and used for biochemical assays. On-column cleavage of GST was performed with PreScission Protease (GE Healthcare), and GST-cleaved purified PHD was dialyzed with assay buffer.
In Vitro Histone Peptide Array, Peptide Pull-Down, and Fluorescence Polarization Assays Peptide microarray experiments were performed as previously described (Koh et al., 2008) . Biotinylated-peptide pull-down assays using recombinant proteins were performed as previously described (Shi et al., 2006) . C-terminal biotinylated peptides (Table S8) were purchased from Millipore. Pull-down assays using nuclear extracts prepared from WT mouse brain using the Dignam protocol (Dignam et al., 1983 ) were performed as previously described (Wysocka et al., 2006) with some modifications. Briefly, brains were dissected from C57BL/6 mice, crushed in liquid nitrogen, and lysed according to the Dignam protocol. Nuclear extracts were precleared with streptavidin beads (Amersham) and incubated with peptide that had been prebound to streptavidin beads for 3 hr at 4 C in binding buffer (20 mM HEPES, pH 7.9 at 4 C, 20% glycerol, 0.15 M KCl, 0.5 mM DTT, 0.2% (v/v) Triton X-100, and protease inhibitor). Approximately 5 mg of peptide was used per pull-down. Beads were washed eight times and the bound proteins were subjected to Coomassie staining and western blot analyses. Fluorescence polarization (FP) experiments were carried out using a Biotek Synergy 4 plate reader (Biotek) at 30 C as previously described (Jacobs et al., 2004 ChIP Assays and ChIP-Seq Analyses Chromatin was prepared from WT MEFs and used for immunoprecipitation. ChIP analyses were performed as described previously (Zeng et al., 2006) with some modifications. For these analyses, 1 3 10 7 cells were used per immunoprecipitation and were sequentially cross-linked with ethylene glycolbis[succinimidyl succinate] (EGS; Thermo Scientific) for 30 m, followed by 1% formaldehyde for 10 m at room temperature. Cross-linking was quenched with glycine, cells were washed and lysed, and chromatin was sheared by sonication. Chromatin was immunoprecipitated with Dyna-beads preconjugated with primary antibodies specific for normal rabbit IgG, Chd5 (M-182), or H3K4me3. The immunoprecipitated samples were washed and eluted, and cross-linking was reversed with 200 mM NaCl for 8 hr. Samples were digested with RNase A and treated with proteinase K before phenol/chloroform extraction, and then used for ChIP-Solexa sequencing (performed at the CSHL Genomics Shared Resource) or qPCR. Samples were analyzed in triplicate by real-time PCR using SYBR green (Quanta Biosciences) on the LightCycler 480 (Roche). To allow comparison among primer sets, unprecipitated input samples from each condition were serially diluted and used as standards for all PCRs. The ChIP-Seq analysis is described in Extended Experimental Procedures.
Cellular Assays
MEFs and SK-N-AS cells were assessed for proliferation by plating 5 3 10 4 cells and 2.5 3 10 4 cells on 6 cm dishes or six-well plates, respectively. Cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 100 mg/ml Hygromycin B (Roche) and 0.5 mg/ml Puromycin (Sigma-Aldrich), and were either untreated or treated with 0.2 mg/ml dox (Sigma). Cells were harvested and each plate was counted in triplicate using a Z1 Coulter particle counter (Beckman-Coulter) or crystal violet staining. Graphs and SEs were obtained with Prism software. Tumorigenesis assays in athymic nude mice were performed as previously described (Bagchi et al., 2007; Hemann et al., 2004) . Briefly, MEFs (0.5 3 10 6 cells) were injected subcutaneously into irradiated athymic nude mice, and dox was administered in food and drinking water (2 mg/ml) for 7 days and continued with dox only in food. Matrigel-mixed 1.6 3 10 6 SK-N-AS cells were injected subcutaneously into two cohorts of irradiated athymic nude mice. One group received a normal diet and the other group received the dox diet 2 days prior to injections and continued on the dox diet for the rest of the experiment. Tumor development was monitored via measurements by a blinded observer, and tumors were harvested and processed for subsequent analysis.
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